OA
NBIX icon

Oak Associates’s Neurocrine Biosciences NBIX Stock Holding History

Oak Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,361
Closed -$1.53M – 135
2022
Q1 		$1.53M Hold
16,361
– – 0.09% 91
2021
Q4 		$1.39M Buy
+16,361
New +$1.51M 0.07% 99

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Oak Associates's NBIX Position: Q2 2022 in Review

Oak Associates sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 16,361 shares — an estimated $1.53M sold.

Oak Associates first reported a position in NBIX in Q4 2021 and held it in 2 quarters. The position peaked at $1.53M in Q1 2022. 437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Oak Associates reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
  • Oak Associates sold 16,361 Neurocrine Biosciences shares in Q2 2022, an estimated $1.53M.
  • Oak Associates first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 2 quarters.
  • Oak Associates's Neurocrine Biosciences position peaked at $1.53M in Q1 2022.
  • 437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Oak Associates's 13F filing for Q2 2022, filed 12 Aug 2022.